Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine and Cisplatin with Radiation in Cervical Cancer
NCT00191100Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- May 2002
- Primary completion
- Apr 2008
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 3, randomised, open-label trial of gemcitabine in Cervical Cancer (CC), sponsored by Eli Lilly and Company. Primary endpoint: Progression-Free Survival at 3 years. Started May 2002; status: completed.
02
Drugs
gemcitabine
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT00191100.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00191100.